EU Says Nitrosamine Risk Info Also Needed For New Drug Filings
Incomplete Info May Impact Granting Of Marketing Authorization
Executive Summary
Companies seeking approval of new drugs must provide information on nitrosamine-related risk evaluation either as part of their marketing application or during the evaluation process.